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Aims Expression and activity of the transcription factor AP-1 are enhanced during cardiac remodelling and heart failure pro-
gression. In order to test if AP-1 inhibition may limit processes contributing to cardiac remodelling, ventricular cardio-
myocytes of mice with cardiac overexpression of the AP-1 inhibitor JDP2 were analysed under stimulation of
hypertrophy, apoptosis, or contractile function.
Methods
and results
Three models of JDP2 overexpressing mice were analysed: JDP2 was overexpressed either life-long, for 7 weeks, or 1
week. Then cardiomyocytes were isolated and stimulated with b-adrenoceptor agonist isoprenaline (ISO, 50 nM).
This enhanced cross-sectional area and the rate of protein synthesis in WT but not in JDP2 overexpressing cardiomyo-
cytes. To induce apoptosis, cardiomyocytes were stimulated with 3 ng/mL TGFb1. Again, JDP2 overexpression pre-
vented apoptosis induction compared with WT cells. Determination of contractile function under electrical
stimulation at 2 Hz revealed enhancement of cell shortening, and contraction and relaxation velocities under increasing
ISO concentrations (0.3–30 nM) in WT cells. This inotropic effect was abrogated in JDP2 overexpression cells. Respon-
siveness to increased extracellular calcium concentrations was also impaired in JDP2 overexpressing cardiomyocytes.
Simultaneously, a reduction of SERCA expression was found in JDP2 mice.
Conclusion A central role of AP-1 in the induction of hypertrophy and apoptosis in cardiomyocytes is demonstrated. Besides these
protective effects of AP-1 inhibition on factors of cardiac remodelling, AP-1-inhibition impairs contractile function.
Therefore, AP-1 acts as a double-edged sword that mediates mal-adaptive cardiac remodelling, but is required for main-
taining a proper contractile function of cardiomyocytes.
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1. Introduction
Cardiac hypertrophy and apoptosis are main predictors and causes for
heart failuredevelopment,whichfinally results in contractile dysfunction
of the heart. Interestingly, all these events are often accompanied by ele-
vations of the transcription factor AP-1: in vivo, increased levels of AP-1
are found under pressure overload,1 in the phase of LV remodelling after
myocardial infarction,2 or after isoprenaline infusion in rats.3
AP-1 is a dimer of jun and fos family members. Thus, dominant-
negative expression of either of these subunits results in the impairment
of AP-1. Using this technique in isolated cardiomyocytes already has
demonstrated an important role of AP-1 in cardiac hypertrophy and
apoptosis. In neonatal cardiomyocytes, Omura et al. 4 expressed
dominant-negative mutant c-jun, resulting in depressed AP-1 activity.
This abrogated hypertrophic responses to endothelin 1 as well as to
thea-adrenoceptor agonist phenylephrine. Dominant-negative expres-
sion of c-Fos, that also blocked AP-1 activity in neonatal cardiomyocytes,
inhibited the induction of the pathological gene profileunder stimulation
with phenylephrine, i.e. blocking expression of beta-myosin heavy chain
and atrial/brain natriuretic peptides (ANP/BNP), and prevented down
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regulation of sarcoplasmic reticulum Ca2+-ATPase (SERCA).5 The
latter finding indicates that AP-1 may, in addition to its role in hyper-
trophic growth, also modulate contractile function of cardiomyocytes.
In adult cardiomyocytes of rat, the involvement of AP-1 in hyper-
trophic growth could be confirmed by the use of decoy-
oligonucleotides, that intracellularly scavenge AP-1, thereby inhibiting
hypertrophic growth under phenylephrine stimulation.6 In addition to
its involvement in hypertrophic signalling, AP-1 contributes to apoptosis
induction, since transfection of adult cardiomyocytes of rat with
AP-1-decoy-oligonucleotides abolished apoptosis under stimulation
with the growth factor TGFb1 or with nitric oxide.
7 In addition to
AP-1, activation of transcription factors of the SMAD family are
needed in order to induce apoptosis in cardiomyocytes. Adenoviral
SMAD4 overexpression in cardiomyocytes can even turn the
a-adrenergic induced, pro-hypertrophic signal of AP-1 into an apoptotic
stimulus.8
To dissect the role of AP-1 in vivo, the working group of Aronheim and
colleagues9 generated a transgenic mice model with cardiac specific
overexpression of the AP-1 inhibitor JDP2 (c-jun dimerization protein
2). Both, JDP2 and AP-1 belong to the b-ZIP family of DNA-binding pro-
teins. AP-1 is formed by the dimerization of jun- and fos-family members,
resulting in a DNA-binding and transcription activating complex. In
hypertrophic or apoptotic ventricular cardiomyocytes, c-Jun, Jun B,
c-Fos, and Fos B were identified as subunits of AP-1 dimers.7 Association
of JDP2 with jun-family members prevents the formation of transcrip-
tion promoting AP-1 dimers.10 Additionally, JDP2 can bind directly to
AP-1-specific promoter elements. This, again results in the abrogation
of AP-1-dependent transcription.
Thus, cardiac-specific JDP2 overexpression results in specific inhib-
ition of AP-1 signalling and may thus interfere with cardiac hypertrophy
andapoptosis. First studieson these transgenicmice, thatoverexpressed
JDP2heart-specifically undercontrolof a tetracycline-regulateda-MHC
promoter, revealed the development of massive atrial dilatation, which
was reversible upon abolishment of JDP2 expression by the tetracycline
system (tet-off-system).9 In histological sections of JDP2 overexpressing
hearts, hypertrophic cardiomyocytes were detected in atria, but not in
the ventricles.
Only under stimulation of ventricular cardiomyocytes with hyper-
trophy or apoptosis inducing agents, AP-1 is up-regulated, and only
under such conditions, JDP2 may interfere with the processes of ven-
tricular remodelling. Therefore, the question arises, if ventricular cardi-
omyocytes of transgenic JDP2 mice are resistant to the induction of
hypertrophy and apoptosis? Furthermore, influence of JDP2 overex-
pression on contractile function of cardiomyocytes was of interest, in
order to get comprehensivedata about effects of AP-1 inhibition on pro-
cesses of ventricular remodelling. To answer these questions, hyper-
trophic growth under b-adrenergic stimulation, apoptosis induction
by TGFb1, and contractile responses to b-adrenoceptor stimulation
or enhanced calcium concentrations were compared in WT and
JDP2-overexpressing cardiomyocytes.
2. Methods
The investigation conforms to the Directive 2010/63/EU of the European
Parliament. Use of animals was registered at the Justus-Liebig-University
(registration-no.: 419-M).
2.1 JDP2 overexpressing mice
JDP2 mice, crossings with the C57BL6/FVB-line, had been generated in Haifa,
Israel. They are double transgenic, carrying a heterocygote JDP2 gene with a
minimal promoter and a heterocygote transactivator gene under the control
of the heart specific a-MHC promoter. The transactivator could be regu-
lated by the antibiotic doxycycline (Dox) in a tet-off system: Feeding the
animals with Dox blocked the interaction between the transactivator and
the promoter of the JDP2 gene, thereby preventing JDP2 overexpression.
To investigate short- and long-term effects of AP-1 inhibition, duration of
JDP2 expression was controlled by Dox-feeding of animals for different
times (Figure 1A). Therefore, three groups with constitutive, chronic, or
acute JDP2 overexpression were generated by the following feeding proto-
cols: In the first group, mice were kept without Dox-feeding their whole life
through. This resulted in an embryonic and life-long, constitutive AP-1 inhib-
ition. In the second group, breeding pairs and newborn mice were fed with
Dox until the first week after birth. This guaranteed the absence of JDP2
overexpression during embryonic and juvenile development of mice,
which was followed bya chronicAP-1 inhibition due to JDP2 overexpression
for 7 weeks. In the third group, breeding pairs and new born mice were fed
with Dox for 10 weeks followed by an acute AP-1 inhibition in the last week
of life. As control, littermates of transgenic mice which did not overexpress
JDP2 (wild-types) were used. Also WT mice received three different
Dox-diet protocols. At the age of 9 weeks, all mice were used for isolation
of hearts or ventricular cardiomyocytes.
2.2 Cell isolation and culture
Mice were anaesthetized by isofluran inhalation. After cervical dislocation
hearts were extracted, and retrograde-perfused in a Langendorff apparatus
with a collagenase-containing calcium-free buffer equilibrated at 378C, pH
7.4. After separation of cardiomyocytes from other cardiac cells by centrifu-
gation, medium was re-adjusted to a physiological calcium concentration
and suspended in basal culture medium. Cardiomyocytes were then
plated on laminin-coated culture dishes. After 2 h, medium was changed
and cells could be stimulated. The basal culture medium (CTT) was
modified medium 199 including Earl´s salts, 2 mM L-carnitine, 5 mol/L
taurine, 100 000 IU/L penicillin, 100 mg streptomycin, and 10 mmol/L
cytosine-beta-L-arabinofuranoside.
2.3 Electrophoretic mobility shift assay
Hearts were homogenized in swelling buffer (10 mM Tris–HCl, pH 7.9,
10 mM KCl, 1 mM MgCl2, and 1 mM DTT). After incubation for 1 h on ice,
nuclei were pelleted by centrifugation at 900 rpm for 10 min. Pellets were
homogenized in 10 mM Tris–HCl, pH 7.9, 300 mM saccharose, 1.5 mM
MgCl2, 1 mMDTT, and0.3%TritonX-100 andagain centrifugedasdescribed
earlier. Pellets were suspended in storage buffer (10 mM HEPES, pH 7.5,
50 mM KCl, 300 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and
20% glycerol) on ice for 30 min and centrifuged at 13 000 rpm at 48C for
5 min. The resulting supernatants were used for retardation assays: TPA re-
sponse element (TRE) oligonucleotides, containing complementary
sequences of the AP-1 binding domain (5´-ATCCGCTTGATGAGTCAGCC
GGAA-3´) were hybridized, fluorescent labelled with Cy3-dCTP, and incu-
bated with nuclear extracts in the presence of 0.5 mg of poly(dIdC) at
308C for 30 min. The samples were run on 4% native polyacrylamide gels.
For the identification of binding proteins, subsequent to the incubation of
nuclear extracts with the oligonucleotide, 0.5 mg of antibodies specific for
JDP2 or c-jun (Santa Cruz) were added to the reaction mixture and incu-
bated for another 30 min at 308C. Gels were exposed on fluorescence
imager (BioRad).
2.4 Real-time PCR
Total RNA from left ventricles was extracted with Trizol (Invitrogen) as
described by the manufacturer. This was followed by DNAse treatment
and reverse transcription with QuantiTect Reverse Transcription Kit from
Quiagen. For each assayed gene, annealing temperature and the number of
cycles resulting in a linear amplification rangewere tested. RT–PCR wasper-
formed in an automated thermal cycler and detected with the Biorad detec-
tion system (Biorad) using SYBR Green fluorescence for quantification. The
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calculations of the resultswere carried out according to the 22DDCt methods
as described.11 Gene expression was related to B2M as housekeeping gene.
The following primers were used: b1-adrenoceptor from Quiagen, b2-
adrenoceptor: 5´-TGGTACCGTGCCACCCACAA-3´, 5´-AAGACCATC
ACCACCAGGGGCA-3´; B2M: 5´-GCTATCCAGAAAACCCCT CAA-3´,
5´-CATGTCTCGATCCCAGTAGACGGT-3´; phospholamban: 5´-GCAAT
ACCTCACTCGCTCGGCTATC-3´, 5´-TGGAGATTCTGACGTGCTTGC
TGAG-3´; NCX: 5´-CTACCAGGTCCTAAGTCAACAG-3´, 5´-TGCGTGC
CTCTTCAAGATG; TGFb1: 5´-GTCCTTGCCCTCTACAACCA-3´, 5´-GT
TGGACAACTGCTCCACCT-3´; SMAD2: 5´-GGAACCTGCATTCTGGT
GTT-3´, 5´-ACGTTGGAGAGCAAGCCTAA-3´; SMAD3: 5´-TTCACTGA
CCCCTCCAACTC-3´, 5´-CTCCGATGTAGTAGAGCCGC-3´; SERCA:
5´-TGACTGGTGATGGTGTGAATG-3´, 5´-GATGAGGTAGCGGATGAA
CTG-3´
2.5 Immunoblot analysis
Proteins were extracted from frozen hearts of transgenic mice with chronic
JDP2 overexpression and from corresponding hearts of WT mice. Hearts
were homogenized in RIPA buffer (50 mmol/L Tris/HCl, pH 7.5,
150 mmol/L NaCl, 1% Nonidet P-40, 0.5% deoxycholat, 0.1% SDS, 1 mM
PMSF, 1 mM EDTA, 1 mg/l pepstatin). Nucleic acids were digested with ben-
zonase. Samples were denatured in Laemmli buffer at 908C for 5 min, loaded
on 12.5% SDS-gels, and blotted on PVDF membranes. For detection of
SERCA2A expression, specific antibodies were purchased from Santa
Cruz. For loading controls, actin antibodies were used. Protein bands
were detected by horseradish peroxidase-labelled secondary antibodies
using ECLas detection system(Pierce). SERCA-specific signals were normal-
ized against actin.
2.6 Hypertrophy assays
Isolated cardiomyocytes were incubated with theb-adrenoreceptor agonist
isoprenaline (ISO, 50 nM) for 24 h. As parameters for hypertrophy,
cross-sectional area and the rate of protein synthesis were used. For meas-
uring the cross-sectional area, myocyte size was determined on micrographs
digitalized by a charge-coupled device camera as described elsewhere.12
Width/diameter of randomly taken cells was determined at the widest
point of each myocyte using the software program Adobe Photoshop 5.5.
Cross-sectional area of cardiomyocytes was calculated by the following
formula: cross-sectional area ¼ radius2 × p.
Todeterminethe rateofprotein synthesis, incorporationof [L-14C]phenyl-
alanine (0.1 mCi/L) over 24 h was analysed. Incorporation of radioactivity
into acid-insoluble cell mass was determined as described previously.13
2.7 Apoptosis assay
To induce apoptosis, cardiomyocytes were incubated with 3 ng/mL of trans-
forming growth factor b1 (TGFb1) for 4.5 h. Then, cells were stained with
annexin V-FITC (10 mL/mL)/propidiumiodide (5 mL/mL) for 15 min. Apop-
totic cardiomyocytes stained with annexin V-FITC, resulting in a green fluor-
escence when exited at 450–480 nm, and excluded propidiumiodide, a
DNA dye unable to pass the plasma membrane. Necrotic cells have lost
their physical integrity of their plasma membrane and appear double-stained
with annexin V-FITC/propidium iodide, which fluoresces in the red
when exited at 510–550 nm. For the quantification of apoptosis and necro-
sis, 200 randomly distributed cardiomyocytes were counted in each
experiment.
2.8 Cell contraction
Cell shortening was analysed as described previously.14 Briefly, cardiomyo-
cytes were incubated with different concentrations of isoprenaline
(0.3–30 nM) or calcium (2.5 and 5 mM), and stimulated at 2 Hz for 1 min
at room temperature. Analysis of cell contraction was performed using
cell-edge detection system. Cells were stimulated via two AgCl electrodes
with biphasic electrical stimuli composed of two equal but opposite rect-
angular 50 V stimuli of 5 ms duration. Only rod-shaped cells that contracted
Figure 1 (A) Regulation of AP-1 inhibition via Dox-feeding in transgenic JDP2 mice. Constitutive JDP2 overexpression resulting in embryonic and life-
longAP-1 inhibition wasachieved in the absenceofDox-diet. In the groupwith chronicAP-1 inhibition, Doxwas fedduring theembryonicdevelopmentand
over the first week after birth. During this time, JDP2 wasnot overexpressed. In the following 7 weeks, mice received Dox-diet no more, resulting in chronic
AP-1 inhibition over 7 weeks. In the acute group, mice were treated with Dox during embryonic development and for 7 weeks after birth. Thus, acute JDP2
overexpression or AP-1 inhibition was present for 1 week only. (B and C) AP-1 and JDP2 binding activity in the hearts of wild-type and JDP2 overexpressing
mice. (B) Nuclear extracts of hearts from WT and JDP2 mice with chronic JDP2 overexpression were prepared and tested in EMSAs for binding activity to
the TRE-oligo. Enhanced binding activity is found in extracts from JDP2 overexpressing mice. (C) Subunit composition of the complex that binds to the
TRE-oligo was analysed. Therefore, c-jun and JDP2 antibodies were added to the binding reaction. Specific antibody-protein interaction reduced the
binding activity to the TRE-oligo.
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regularly during the whole time of measurement were used. Every 15 s, cell
shortening, contraction, and relaxation velocity were measured using a line
camera. The mean of four measurements per cell was used as average value
of each individual cardiomyocyte. Cell-shortening data were normalized to
the individual diastolic cell length (dL/L %).
2.9 Statistics
Data are given as means+ standard deviation from n different culture pre-
parations. Statistical comparisons were performed by ANOVA (One-Way
Analysis of Variance) and Tukey-test or Student’s t-test. A P-value of
,0.05 was considered statistically significant.
3. Results
3.1 Constitutive JDP2 overexpression
represses hypertrophic growth and
apoptosis
First, we analysed the effects of life-long, constitutive JDP2 overexpres-
sion on hypertrophy and apoptosis. Therefore, animals were fed with a
regular diet without Dox supplementation, so that already during em-
bryogenesis and juvenile development, as well as in adult mice, JDP2
was overexpressed. Thus, AP-1 was inhibited in all these stages
(Figure 1A). Ventricular cardiomyocytes of 9-week-old adult wild-type
and transgenic JDP2 mice were isolated. As can be seen in Figure 2A
and B, continuous JDP2 overexpression had no influence on hyper-
trophic growth, because in the absence of any stimulation, the cardio-
myocyte size of WT and JDP2 mice are similar. As was shown by Sabri
et al., 15 cardiomyocytes of mice develop hypertrophic growth upon
b-adrenergic stimulation. Therefore, we used the b-adrenoceptor
agonist isoprenaline (ISO) for growth stimulation. Prior to ISO stimula-
tion, mRNA expression of b-adrenoceptors in left ventricles was
analysed to be sure that JDP2 overexpression does not influence
b-adrenoceptor expression. As determined by RT–PCR, JDP2 and
WT mice expressed the same b1- and b2-adrenoceptor levels
(0.97-and 1.04-fold in JDP2 vs. WT left ventricles, n ¼ 5, n.s.). Then, car-
diomyocytes were stimulated with ISO (50 nM) for 24 h, and the cross-
sectional area was determined as a parameter for hypertrophic growth.
In WT cardiomyocytes, ISO increased the cross-sectional area
compared with unstimulated control cells to 116.7+ 15.7% (n ¼ 7;
P, 0.05 vs. control). In contrast, JDP2 overexpressing cardiomyocytes
were protected against enlargement of cross-sectional area under ISO
(103+6.8% n ¼ 6; n.s. vs. control) (Figure 2). To confirm these findings,
the rate of protein synthesis, as another parameter for hypertrophic
growth, was determined. In WT cardiomyocytes, incorporation of
14C-phenylalanine over 24 h was enhanced by ISO (50 nM) to
117.9+ 10.5%, (n ¼ 15; P, 0.05 vs. control) (Figure 2B). Cardiomyo-
cytes of transgenic JDP2 mice did not show an increase in
14C-phenylalanine incorporation upon ISO stimulation (99.9+ 18.8%;
n ¼ 11; P, 0.05 vs. control).
In order to analyse the effects of JDP2 overexpression on apoptosis
induction, transforming growth factor beta (TGFb1) was chosen as an
apoptotic stimulus, because TGFb1 is found up-regulated during
cardiac remodelling and is known to induce apoptosis in rat cardiomyo-
cytes via AP-1/SMAD signalling.7 To be sure that TGFb/SMAD signalling
is not influenced by JDP2 overexpression per se, mRNA expression of
TGFb1, SMAD2, and SMAD3 in the left ventricles of WT and JDP2
mice were compared. RT–PCR revealed no overt changes in the ex-
pression of TGFb1-mRNA (0.8-fold vs. WT ventricles, n ¼ 5, n.s.),
SMAD2-mRNA (1.7-fold vs. WT ventricles, n ¼ 7, n.s.), and
SMAD3-mRNA (1.5-fold vs. WT ventricles, n ¼ 7, n.s.).
ThenventricularcardiomyocytesofWTand JDP2overexpressingmice
were stimulated with 3 ng/mL TGFb1 for 4.5 h, and apoptosis was
detected by staining with annexin and propidiumiodid. In WT cardiomyo-
cytes, TGFb1 enhanced apoptosis from 0.8+0.6% in control to 1.6+
1.1% (n ¼ 25; P, 0.05 vs. control) (Figure 3). In cardiomyocytes overex-
pressing the AP-1 inhibitor JDP2, TGFb1 did not induce apoptosis (0.5+
0.5% apoptotic cells in unstimulated controls vs. 0.6+0.6% in stimulated
JDP2 cells; n ¼ 7; n. s. vs. unstimulated controls).
Thus, constitutive, life-long inhibition of AP-1 by JDP2 prevents induc-
tion of hypertrophic growth and apoptosis in ventricular cardiomyocytes.
3.2 Chronic or acute JDP2 overexpression
represses hypertrophic growth and
apoptosis
Constitutive overexpression of any transgene may interfere with the
developmental processes which may provoke many changes in organ
systems and cell signalling. Although we could not find obvious
Figure 2 Constitutive JDP2 overexpression protects cardio-
myoytes against hypertrophic growth. Cardiomyocytes of WT and
constitutively JDP2 overexpressing mice were stimulated with 50 nM
ISO for24 h. (A)RepresentativepicturesofWT(a, b) and constitutively
JDP2 overexpressing cardiomyocytes (c, d). Only in WT cardiomyo-
cytes an increase in cell size was visible after stimulation with ISO. (B)
For quantitative analysis of hypertrophic growth, the cross-sectional
area of cardiomyocytes (WT: n ¼ 7, JDP2: n ¼ 6) and the rate of
protein synthesis (WT: n ¼ 15, JDP2: n ¼ 7) were determined. Data
are means+ SD of n independent preparations. *Differences from un-
stimulated controls with P, 0.05. #Differences between stimulated
WT and JDP2 overexpressing cardiomyocytes with P, 0.05.
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differences in cell size or apoptotic parameters of mice constitutively
overexpressing JDP2 compared with WT mice, we wanted to exclude
any developmental side effects of JDP2 overexpression. Therefore,
breeding pairs and newborn mice were fed with Dox until the first
week after birth. This guaranteed the absence of JDP2 overexpression
during embryonic and juvenile development of mice, followed by a
chronic phase of JDP2 overexpression.
For confirmation of efficient JDP2 overexpression, binding activity in
nuclear extracts of WT- and JDP2-overexpressing hearts to the TRE
oligo was analysed in electrophoretic mobility shift assays (EMSAs). As
depicted in Figure 1B, JDP2 overexpression enhanced binding to the
TRE oligo. Densitometric analysis of these band shifts revealed a
127+10% increased binding activity in JDP2 mice (n ¼ 3, P, 0.05 vs.
WT). Since JDP2 can form heterodimers with c-jun in order to bind
to the TRE sequence, we analysed subunit composition of the binding
complex by the use of specific antibodies. While the band shift from
nuclear extracts of WT mice was reduced by c-jun antibodies only,
the shift from nuclear extracts of JDP2 mice was reduced by c-jun and
JDP2 antibodies (Figure 1C). This indicates that enhanced binding activity
in JDP2 mice is due to JDP2 overexpression. Binding of c-jun/JDP2 het-
erodimers or JDP2 alone to AP-1 binding sites can then block
AP-1-mediated gene transcription.
In addition to the constitutive andchronic JDP2overexpression, itwas
of interest, if short-term overexpression may be sufficient for protective
effects on cardiomyocytes. Therefore, a third group of animals received
continuous Dox feeding. One week prior to the isolation of cardiomyo-
cytes, Dox feeding was stopped resulting in an acute AP-1 inhibition in
these animals (Figure 1A).
Cardiomyocytes of micewith chronic and acute JDP2 overexpression
were stimulated with 50 nM ISO for the induction of hypertrophic
growth. As depicted in Figure 4, this stimulation did not enhance
the cross-sectional area or the rate of protein synthesis. Thus, cardio-
myocytes of chronic or acute overexpressing JDP2 micewere protected
against hypertrophic growth stimulation. Furthermore, chronic or acute
JDP2 overexpression protected cardiomyocytes against apoptosis
induction, since TGFb1 (3 ng/mL) did not increase the number of apop-
totic cells for these mice (Figure 5).
3.3 JDP2 overexpression impairs contractile
function of cardiomyocytes
Induction of cardiac hypertrophy and apoptosis finally results in heart
failure that is associated with contractile dysfunction. Therefore it was
of interest, if AP-1 inhibition by JDP2 overexpression may influence con-
tractile function of cardiomyocytes, and the contractile response to
b-adrenergic stimulation with ISO was then tested.
Cardiomyocytes ofWTmice responded to increasing ISOconcentra-
tions with enhanced cell shortening, reaching a maximum cell shortening
of 14.6+ 3.1%dL/L at 30 nM ISO (P, 0.05 vs. unstimulated control
with 7.5+ 3.1%dL/L). This observation goes along with an enhance-
ment of contraction and relaxation velocity (Figure 6). In cardiomyocytes
of mice with chronic JDP2 overexpression, contraction parameters at
low ISO levels (0.3–10 ng ISO) were already decreased (Figure 6).
This impaired contractile responsiveness to ISO stimulation was even
more pronounced at higher ISO concentrations. Even 30 nM ISO did
not increase cell shortening in cardiomycytes of JDP2 mice (7.4+2.0
with 30 nM ISO vs. 6.3+ 3.1 unstimulated, n.s., n ¼ 54 cells). This indi-
cates that AP-1-inhibition abrogates positive contractile responses to
b-adrenergic stimulation of cardiomyocytes. To analyse, if contractile
function is also reduced in the presence of other stimuli, cardiomyocyte
contraction under increased calcium concentration was investigated.
Also here, a strong enhancement of cell shortening was found in WT
cells (10.2+2.5%dL/L under 2.5 mM calcium vs. 13.6+2.7 under
5 mM calcium, P, 0.05, n ¼ 27). In JDP2 overexpressing cardiomyo-
cytes, cell shortening was already reduced at 2.5 mM calcium
(6.7+ 1.8%dL/L, P, 0.05 vs. WT, n ¼ 27), and remained significantly
reduced at higher calcium concentrations (8.8+ 2.4%dL/L, P, 0.05
vs. WT, n ¼ 27) (Figure 6B).
Such reduced contractile responses can be due to altered calcium
handling in the cell. The main determinant of calcium handling in cardio-
myocytes is the calcium pump SERCA, which is regulated by phospho-
lamban. Therefore, we compared their mRNA expression levels in left
ventricles of WT and chronically JDP2 overexpressing mice. While
PLB mRNA-expression and expression of the sodium–calcium exchan-
ger NCX was unaffected, SERCA2A-expression was reduced 0.4-fold
(P, 0.05 vs. WT, n ¼ 5) in the left ventricles of JDP2 overexpressing
mice. In western blots, reduction of SERCA2A was confirmed on the
protein level: SERCA2A was found reduced to 59.5+13.4% in the
hearts of JDP2 mice (P, 0.05 vs. WT, n ¼ 4).
4. Discussion
The main findings of our studyare that AP-1 inhibition protects ventricu-
lar cardiomyocytes against the induction of hypertrophy and apoptosis.
But simultaneously, AP-1 inhibition depresses contractile responses to
b-adrenergic stimulation or increased calcium concentrations. Thus,
AP-1 is identified as a mediator of mal-adaptive responses in cardiac re-
modelling. But at the same time it is required to maintain proper con-
tractile function of cardiomyocytes. Therefore, care should be taken
Figure 3 Constitutive JDP2 overexpression protects cardiomyo-
cytes against TGFb1-induced apoptosis. Cardiomyocytes of WT and
JDP2 overexpressing mice were incubated with 3 ng/mL TGFb1 for
4.5 h. Cells were stained by annexin/propidiumiodide, and apoptotic
cells were counted. Data are means+ SD of n independent prepara-
tions (WT: n ¼ 25, JDP2: n ¼ 7). *Differences from unstimulated con-
trols with P, 0.05.
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when thinking about the use of AP-1 inhibitors for the prevention of
cardiac remodelling.
In this study, we used transgenic JDP2 mice in order to analyse the
effects of AP-1-inihibition on hypertrophic growth, apoptosis induction,
and contractile function of ventricular cardiomyocytes. In these mice,
JDP2 expression is under the control of the a-MHC promoter, which
guarantees cardiac-specific overexpression. Efficient JDP2 overexpres-
sion in the hearts of these mice has already been demonstrated by
Kehat et al. 9 using western blots and immunofluorescence. We now
demonstrate in EMSAs that the binding activity to AP-1 binding sites
(TRE) is enhanced in the nuclear extracts of JDP2 mice. Since JDP2
cannot promote gene transcription, binding of JDP2 will block
AP-1-mediated gene transcription. However, this seems to be a partial
inhibition since JDP2 antibodies could not totally abolish the binding ac-
tivity to the TRE-oligo.
Phenotypic characterization of these mice revealed atrial dilatation.
However, no ventricular phenotype was obvious, although involvement
of AP-1 in hypertrophic growth and apoptosis of cardiomyocytes was
demonstrated by different groups. We also did not detect any sign of
hypertrophic growth, since cell size was similar in WT and JDP2 overex-
pressing cardiomyocytes. Furthermore, TGFb1 and SMAD2/3 expres-
sion, factors that are involved in AP-1-mediated apoptosis induction,
were not elevated in the left ventricles of JDP2 mice. In addition, the
levels of apoptosis in WT and JDP2 overexpressing cardiomyocytes
were similar.
Induction of AP-1 expression and activity is found under pathophysio-
logical conditions in the heart. This indicates that AP-1 may be of import-
ance only, if pathophysiological stimuli are present in the heart. Since
analysis of transgenic JDP2 mice was performed in the absence of any
pathogenic stimulation, the lack of ventricular phenotypes does not sur-
prise. Therefore, in this study, cardiomyocytes of JDP2 overexpressing
mice were stimulated by factors that are known to induce hypertrophy
or apoptosis in cardiomyocytes via AP-1 signalling. Since JDP2 overex-
pression could be blocked by feeding mice doxocycline, we had the
opportunity to distinguish groups with (i) constitutive, life-long overex-
pression, (ii) with chronic overexpression for 7 weeks, and (iii) one
group with JDP2 overexpression for 1 week prior to the isolation of car-
diomyocytes. As described by Kehat et al.,9 7 days are required for JDP2
re-expression following doxycycline treatment.
Figure 4 Protection against hypertrophic growth stimulation under chronic and acute JDP2 overexpression. Cardiomyocytes of WT and JDP2 over-
expressing mice were stimulated with 50 nM ISO for 24 h. As parameters of hypertrophic growth, cross-sectional area and rate of protein synthesis
were determined. Data areexpressed asper cent increase relative to untreated controls (dashed line). Data aremeans+ SD ofn independent preparations
(cross-sectional area: WT: n ¼ 18, JDP2: n ¼ 10; acute: WT and JDP2: n ¼ 8; protein synthesis: chronic: WT: n ¼ 19, JDP2: n ¼ 11; acute: WT: n ¼ 18,
JDP2: n ¼ 11). *Differences from unstimulated controls with P, 0.05. #Differences between stimulated WT and JDP2 overexpressing cardiomyocytes
with P, 0.05.
Figure5 Protection against apoptosis under chronic and acute JDP2
overexpression. Cardiomyocytes of WT and JDP2 overexpressing
mice were incubated with 3 ng/mL TGFb1 for 4.5 h. Cells were
stained by annexin/propidiumiodide, and apoptotic cells were
counted. Data are means+ SD of n independent preparations
(chronic: WT: n ¼ 10, JDP2: n ¼ 13; acute: WT and JDP2: n ¼ 11).
*Differences from unstimulated controls with P, 0.05.
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Stimulation of cardiomyocytes with the b-adrenoceptor agonist iso-
prenaline induced hypertrophic growth only in WT, but not in JDP2 over-
expressing cardiomyocytes. This demonstrates that AP-1 inhibition
prevents hypertrophic growth. Interestingly, in freshly isolated cardio-
myocytes of rats, AP-1 dependence of hypertrophy was shown only
under a-adrenergic and not under b-adrenergic stimulation.6 This may
be explained by a different receptor distribution among the two
species.The ratiobetweeneithera- andb-orbetweenb1- andb2- recep-
tors of cardiomyocytes has been shown to be different in mice or rat.16
Furthermore, a generalized defect in a1-adrenoceptor signalling was
described in mice cardiomyocytes.15 These findings explain why hyper-
trophy is coupled toa-adrenoceptors in ratsbut not inmice. Independent
of the hypertrophic stimulus, via a-adrenoceptors in rats or via
b-adrenoceptors in mice, AP-1 is a mediator of the growth response in
both situations. Thus, we can conclude that adrenergically induced hyper-
trophic growth signalling in cardiomyocytes is primarilymediatedvia AP-1
signalling. Abrogation of AP-1 signalling can, therefore, prevent hyper-
trophic growth, that is one major predictor for heart failure development.
A further factor, contributing to heart failure progression is apoptosis.
TGFb1, which has been shown to induce apoptosis in ventricular
Figure6 Chronic JDP2 overexpression impairs contractile responses. Cardiomyocyte contractions from WTand chronically JDP2 overexpressing mice
were analysed at 2 Hz for 1 min at room temperature. (A) Cardiomyocytes were incubated with different concentrations of isoprenaline (0.3, 1, 3, 10, and
30 nM). Cell shortening, as well as contraction and relaxation velocities were determined. Cell shortening was normalized to the individual diastolic cell
length (dL/L %). Data are means+ SD of 54 cells from two independent culture preparations. *Differences from unstimulated controls with P, 0.05.
#Differences between WT and JDP2 overexpressing cardiomyocytes with P, 0.05. (B) Single-cell recordings of cell shortening at 2 Hz are depicted.
Cardiomyocytes were incubated with 30 nM isoprenaline (30 nM) or calcium (2.5 and 5 mM).
AP-1 mediates cardiomyocyte hypertrophy and apoptosis 127
by guest on Decem
ber 23, 2014
D
ow
nloaded from
 
cardiomyocytes of rat, also induces apoptosis in cardiomyocytes of WT
mice. This induction was abrogated in JDP2 overexpressing cardiomyo-
cytes. This protection was independent from the time point of JDP2
overexpression. These findings reveal a central role of AP-1 in apoptotic
processes in the heart.
Besides the effects on hypertrophy and apoptosis, a major determin-
ant of pump function is the contractile functionof cardiomyocytes them-
selves. Indications that AP-1 may also control this parameter, come from
studies in neonatal cardiomyocytes: expression of dominant negative
c-Fos in these cells has been shown to influence SERCA expression, a
calcium transporter that is controlling the main calcium reservoir for
cardiomyocytes contraction.5 Now, in our study, we show that con-
tractile function of cardiomyocytes, determined as percent cell shorten-
ing, as well as contraction and relaxation velocities under electric
stimulation at 2 Hz, are slightly decreased in JDP2 overexpressing cardi-
omyocytes. This reduced contractile response due to AP-1 inhibition
gets even more pronounced, when cells are stimulated with isopren-
aline. While WT cardiomyocytes show an enhanced cell shortening
and faster contraction and relaxation velocities with increasing
amounts of isoprenaline, JDP2 overexpressing cells fail to respond to
b-adrenergic stimulation. Since the expression of b-adrenoceptors in
WT and JDP2-overexpressing ventricles was the same, the reduced
b-adrenergic responsiveness must be due to other reasons. And
indeed, abrogation of contractile responses was also detected when ex-
posing JDP2 cardiomyocytes to increased calcium concentrations.
Lookingat genes related tocontraction, adecrease inSERCAexpression
is evident in JDP2 overexpressing cardiomyocytes. This can cause a re-
duction in Ca2+-reuptake in the sarcoplasmatic reticulum. The internal
cellular Ca2+-reservoir is thereby decreased and the cell is unable to
respond to inotropic stimulations.
In human end-stageheart failure, like in dilatedor ischaemic cardiomy-
opathies, a chronic AP-1 activation is found.2 Our results now suggest
that this AP-1 activation may contribute to hypertrophic and apoptotic
processes in the human heart, thereby provoking adverse cardiac re-
modelling. Thus, treatment of patients with AP-1 inhibitors might
reduce these remodelling processes. However, due to the additional
positive action of AP-1 on cardiomyocyte contractile function, AP-1 ac-
tivity should not be blocked continuously.
In conclusion, using transgenicmiceoverexpressing theAP-1 inhibitor
JDP2, a central role of AP-1 in the induction of hypertrophy and apop-
tosis in cardiomyocytes is demonstrated. Besides these protective
effects of AP-1 inhibition on factors promoting cardiac remodelling,
AP-1-inhibition negatively influences cardiomyocytes by impairment
of contractile function. Thus, when thinking about the development of
AP-1 inhibitors for the prevention of cardiac remodelling care should
be taken.
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